Abdominal Radiology

, Volume 44, Issue 10, pp 3480–3485 | Cite as

Iatrogenic celiac and hepatic artery dissections during intra-arterial regional tumor therapies: a 16-year retrospective review

  • Erica S. AlexanderEmail author
  • Gregory J. Nadolski
  • Michael C. Soulen
  • S. William Stavropoulos
  • Stephen J. Hunt
  • Terence P. Gade
  • Maxim Itkin
  • Susan Shamimi-Noori
Interventional Radiology



To identify the incidence and outcomes of iatrogenic celiac and hepatic artery dissections during transarterial therapies, including bland embolization, chemoembolization, radioembolization (TARE), and pre-TARE scintigraphic mapping.


The institution’s quality assessment database, electronic medical record, and picture archiving and communication system were reviewed to identify all patients who underwent transarterial locoregional therapy from 1/2001 to 7/2017 and to determine the incidence of iatrogenic dissection, to assess patency of the arteries after dissection, and to assess the ability to complete therapy.


2253 patients underwent 3776 transarterial hepatic oncology procedures. Among 3776 procedures, 40 (1.1%) were associated with dissection of the visceral vasculature, affecting 39 patients (1.7%). The incidence of flow-limiting dissections was 0.3% (13/3776) and non-flow-limiting dissections was 0.7% (27/3776). After dissection, 68% (27/40) of treatments were completed the same day. Among the 13 aborted treatments, 8 (62%) were completed on a subsequent encounter. Follow-up imaging was obtained in 26 of 40 cases at median time of 63 days. Complete resolution of the dissection was seen in 15/26 cases (58%), near complete resolution (< 30% luminal narrowing) in 3/26 (12%), unchanged appearance of a non-flow-limiting dissection in 4/26 (15%), progressive luminal narrowing in 3/26 (12%), and complete occlusion in 1/26 (4%).


Iatrogenic dissections of visceral arteries rarely occur during tumor embolization procedures. 35/39 (90%) of patients underwent successful treatment despite the dissection.


Arterial dissection Transarterial chemoembolization Transarterial radioembolization Bland embolization 


Compliance with ethical standards

Conflict of interest

Erica Alexander declares that she has no conflicts of interest. Gregory Nadolski receives research support from Guerbet LCC and Teleflex. Michael Soulen receives research support from Guerbet LCC and BTG International, is a consultant for Guerbet LCC and Genentech, and is a proctor for Sirtex. S. William Stavropoulos is a consultant for Becton–Dickinson and receives research support from Cook and Sillajen. Stephen Hunt is a consultant for BTG and receives research grants from BTG, SIO, SIR, and RSNA. Terence Gade is a consultant for Trisalus and received an investigator initiation grant from Guerbet LLC. Max Itkin has no related conflicts to declare. Susan Shamimi-Noori is a proctor for Sirtex.


  1. 1.
    Kwan SW, Kerlan RK, Jr., Sunshine JH (2010) Utilization of interventional oncology treatments in the United States. J Vasc Interv Radiol 21 (7):1054-1060. CrossRefGoogle Scholar
  2. 2.
    Sun JY, Yin T, Zhang XY, Lu XJ (2019) Therapeutic advances for patients with intermediate hepatocellular carcinoma. J Cell Physiol 234 (8):12116-12121. CrossRefGoogle Scholar
  3. 3.
    Kouri BE (2018) Interventional Oncology: Optimizing Transarterial Therapies for the Treatment of Hepatic Malignancy. Tech Vasc Interv Radiol 21 (4):205-222. CrossRefGoogle Scholar
  4. 4.
    Ma J, Gimenez JM, Sandow T, Devun D, Kirsch D, Gulotta P, Gilbert P, Kay D (2017) Intraarterial Liver-Directed Therapies: The Role of Interventional Oncology. Ochsner J 17 (4):412-416Google Scholar
  5. 5.
    Berger DH, Carrasco CH, Hohn DC, Curley SA (1995) Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 60 (2):116-121CrossRefGoogle Scholar
  6. 6.
    Tu J, Jia Z, Ying X, Zhang D, Li S, Tian F, Jiang G (2016) The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma. Medicine (Baltimore) 95 (49):e5606. CrossRefGoogle Scholar
  7. 7.
    Sakamoto I, Aso N, Nagaoki K, Matsuoka Y, Uetani M, Ashizawa K, Iwanaga S, Mori M, Morikawa M, Fukuda T, Hayashi K, Matsunaga N (1998) Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 18 (3):605-619. CrossRefGoogle Scholar
  8. 8.
    Peterson JL, Vallow LA, Johnson DW, Heckman MG, Diehl NN, Smith AA, Tzou KS, Paz-Fumagalli R, Kim S, Ko SJ, Daugherty LC, Kim GP, Brown N, Mori KW, Buskirk SJ (2013) Complications after 90Y microsphere radioembolization for unresectable hepatic tumors: An evaluation of 112 patients. Brachytherapy 12 (6):573-579. CrossRefGoogle Scholar
  9. 9.
    Onizuka H, Sueyoshi E, Ishimaru H, Sakamoto I, Uetani M (2017) Arterial injury during transcatheter arterial chemoembolization for hepatocellular carcinoma: predictors of risk and outcome. Abdom Radiol (NY) 42 (10):2544-2550. CrossRefGoogle Scholar
  10. 10.
    Yoon DY, Park JH, Chung JW, Han JK, Han MC (1995) Iatrogenic dissection of the celiac artery and its branches during transcatheter arterial embolization for hepatocellular carcinoma: outcome in 40 patients. Cardiovasc Intervent Radiol 18 (1):16-19CrossRefGoogle Scholar
  11. 11.
    Jung E, Shin JH, Kim JH, Yoon HK, Ko GY, Sung KB (2017) Arterial dissections during transcatheter arterial chemoembolization for hepatocellular carcinoma: a 19-year clinical experience at a single medical institution. Acta Radiol 58 (7):842-848. CrossRefGoogle Scholar
  12. 12.
    Gee M, Soulen MC (2002) Chemoembolization for hepatic metastases. Tech Vasc Interv Radiol 5 (3):132-140. CrossRefGoogle Scholar
  13. 13.
    Chao C, Stavropoulos SW, Mondschein JI, Dagli M, Sudheendra D, Nadolski G, Soulen MC (2017) Effect of Substituting 50% Isovue for Sterile Water as the Delivery Medium for SIR-Spheres: Improved Dose Delivery and Decreased Incidence of Stasis. Clin Nucl Med 42 (3):176-179. CrossRefGoogle Scholar
  14. 14.
    de Baere T, Arai Y, Lencioni R, Geschwind JF, Rilling W, Salem R, Matsui O, Soulen MC (2016) Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion. Cardiovasc Intervent Radiol 39 (3):334-343. CrossRefGoogle Scholar
  15. 15.
    Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18 (7):847-855. CrossRefGoogle Scholar
  16. 16.
    Brown DB, Nikolic B, Covey AM, Nutting CW, Saad WE, Salem R, Sofocleous CT, Sze DY, Society of Interventional Radiology Standards of Practice C (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23 (3):287-294.
  17. 17.
    Clark TW (2006) Complications of hepatic chemoembolization. Semin Intervent Radiol 23 (2):119-125. CrossRefGoogle Scholar
  18. 18.
    Maeda N, Osuga K, Mikami K, Higashihara H, Onishi H, Nakaya Y, Tatsumi M, Hori M, Kim T, Tomoda K, Nakamura H (2008) Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med 26 (4):206-212. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Erica S. Alexander
    • 1
    Email author
  • Gregory J. Nadolski
    • 1
  • Michael C. Soulen
    • 1
  • S. William Stavropoulos
    • 1
  • Stephen J. Hunt
    • 1
  • Terence P. Gade
    • 1
  • Maxim Itkin
    • 1
  • Susan Shamimi-Noori
    • 1
  1. 1.Department of Interventional RadiologyHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations